|
A phase 1/2 study with birinapant in combination with pembrolizumab. |
|
|
Consulting or Advisory Role - Celsion; Clovis Oncology; Merrimack |
|
|
|
Stock and Other Ownership Interests - Medivir |
Patents, Royalties, Other Intellectual Property - Medivir |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Access Oncology; Amgen; Cardinal Health |
Consulting or Advisory Role - Access Oncology; Amgen; Cardinal Health |
Research Funding - Gilead Sciences; Ignyta; Incyte; Oncopeptides; Pfizer; Regeneron; Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Access Oncology; Amgen; Cardinal Health |
|
|
|
|
|
|
|
|
|